Ahmann AJ, et al. - This study was coordinated to compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended-release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. After 56 weeks of treatment, semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight. The drugs had comparable safety profiles. These outcomes showed that for subjects with type 2 diabetes who were inadequately controlled on oral antidiabetic drugs, semaglutide treatment was highly effective.